Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I see my thread is being spammed.
If they can connect the two zones they are drilling with similar grades then I believe they will have 75 million oz or so in the ground. That would bring the share price up over $2.00 a share.
Watch for INM this week. There should be more drill results out for La Cigarra. I think this will be huge.
Good year for snow. Long cold winter tho!
That's what I call a low cut-off
Look who's back !!
Panorama was great this time around. Much better conditions!
How about you John? Skiing much? We're headed to Panorama this weekend.
Time for this one to move again soon?
No, just not using this site much right now. I'll be back though eventually.
Nope. Been to Panorama once. Going back at the end of the month. You?
Wow, lotsa snow eh?
Don't hang around here much anymore. Merry Christmas.
Anybody home?
LOL
PharmaGap 1,293,462 shares for debt
2010-09-16 19:56 ET - Shares for Debt
Further to the TSX Venture Exchange bulletin dated July 9, 2009, PharmaGap Inc. has confirmed that the proposed debt settlement of $215,201.44 was not settled as disclosed in the company's news release dated July 16, 2009. The company is now seeking to settle debt in the amount of $219,888.62 to the same creditor. As a result, the exchange has accepted for filing the company's proposal to issue 1,293,462 shares at a deemed price of 17 cents per share to settle outstanding debt for $219,888.62.
PharmaGap Announces Completion of Private Placement
Ottawa, Ontario/ September 14, 2010 – PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF) (“PharmaGap” or “the Company”) announced today that it has completed the second tranche of an offering of equity units (the “Units”). A total of up to 16,666,667 Units were made available to subscribers at the offering price of $0.18. Each Unit consists of one common share and one warrant to purchase a common share at an exercise price of $0.25 for the first two years and $0.35 for the third year of the three year warrant term. PharmaGap announced the first closing of the private placement (which occurred on August 27, 2010) in a news release dated August 30, 2010.
The second closing is in the amount of $304,278 being 1,690,433 Units, to accredited investors, and is subject to final TSX-V approval.
In connection with this second closing of the private placement, cash finder’s fees and broker warrants will be paid to Capital Street Group ($9,128 cash fees and 50,712 broker warrants), to Northern Securities ($630 cash fees and 3,500 broker warrants) to Canaccord Genuity Corp. ($7,649 cash fees and 42,498 broker warrants), and to Wellington West Financial Inc. ($13,020 cash fees and 72,333 broker warrants. Broker warrants are issued on the same terms and conditions as the warrants included in the Units.
For the first and second closings combined, a total of 4,429,750 Equity Units were issued for total gross proceeds of $797,355. For the combined closings, cash finder’s fees and broker warrants have been or will be paid to Capital Street Group ($30,612 cash fees and 170,068 broker warrants), to Northern Securities ($10,458 cash fees and 58,100 broker warrants), to Canaccord Genuity Corp. ($14,934 cash fees and 82,972 broker warrants), and to Wellington West Financial Inc. ($13,020 cash fees and 72,333 broker warrants).
The Units and broker warrants issued pursuant to the Private Placement are subject to a trading restriction for a period of four months and one day from the respective dates of closing.
With the second closing, the private placement initially announced on August 11, 2010 has now been completed and no further Units will be issued pursuant to this placement.
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. PharmaGap’s GAP-107B8 is a novel peptide drug that has been shown to be highly cytotoxic to numerous cancer types, including chemo-resistant cancers, in vitro. For more information on PharmaGap please visit the Company's website at www.pharmagap.com.
For information relating to this Release, please contact:
Robert McInnis, President & CEO
(613) 990-9551 bmcinnis@pharmagap.com
Note: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.
Not going anywhere until the financing uncertainty is resolved.
Golf - How about Sept 3rd ??
Have a great time.
Work or holidays?
When is it not raining? Off to Golden next weekend.
Time to get together for a game? How about July 16th?
Played Grey Wolf and the Radium Springs Course on the weekend. Other than that, played at Elk Island a couple of times and once at Country Side.
Playing much?
OTTAWA, ONTARIO--(Marketwire - June 28, 2010) -PharmaGap Inc. (TSX VENTURE:GAP) (OTCBB:PHRGF) ("PharmaGap" or "theCompany") today announced the appointment of Mr. Ian Malone to its Board of Directors at the Company's Annual General Meeting in Ottawa. Mr.Malone has extensive finance and biotech industry experience and will bring key insights to the Board of PharmaGap as it proceeds toward clinical trials and out-licensing of its lead cancer drug GAP-107B8.
At the Annual General Meeting, in response to a question from a shareholder, Mr. Rod Bryden, Chairman of the Company, disclosed that the Company is looking to further expand its Board to add drug licensing experience. The Company also expects to appoint an experienced Executive to lead Clinical Development in the third quarter.
Mr. Bryden said "We are in the home stretch of bringing our lead drug to clinical trials. Recent test results have stimulated interest with potential licensees and highlighted the need for dedicated clinical development leadership to carry the final pre-clinical program to successful conclusion. We also recognize that a partnership with an established Pharma is the best path to bring this drug treatment to patients and to realize value for shareholders. Mr. Malone will add a new dimension to our Board and we will seek also to attract someone with drug licensing experience. This broadened Board and the addition of an experienced Vice President Clinical Development will position Pharmagap for the opportunities and challenges ahead".
The full presentation made at the Annual General Meeting maybe downloaded at www.pharmagap.com.
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is abiotechnology company with a core focus on developing novel peptidetherapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is anovel peptide drug that has been shown to be highly cytotoxic tonumerous cancer types, including chemo-resistant cancers, in vitro.For more information on PharmaGap please visit the Company's website atwww.pharmagap.com.
Note: Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracy ofthis release. No Securities Commission or other regulatory authorityhaving jurisdiction over PharmaGap has approved or disapproved of theinformation contained herein. This release contains forward lookingstatements that may not occur or may change materially.
OTTAWA,ONTARIO--(Marketwire - June 24, 2010) - PharmaGap Inc. (TSXVENTURE:GAP)(OTCBB:PHRGF) ("PharmaGap" or "the Company") todayannounced 80% average growth inhibition (at 20 micromolar dose) in invitro testing of its lead cancer drug GAP-107B8 in Ocular andCutaneous Melanoma at Memorial Sloan-Kettering Cancer Center (MSKCC).
"In addition to seeing these strong in vitro resultsin melanoma, we are very excited to learn that the test program atMSKCC will proceed to animal tests, and I anticipate results from thesetests during our 3rd quarter", said, President RobertMcInnis.
"We are seeing promising results in the melanoma cell linepanel, and I am excited to be continuing with further testing, both invitro and in animal models, to explore the potential for this newdrug compound," stated Dr. Gary Schwartz, chief of the Melanoma andSarcoma Service at Memorial Sloan-Kettering Cancer Center.
In these tests, GAP-107B8 was tested in cell proliferationassays in 6 Ocular Melanoma and 4 Cutaneous Melanoma human cancer celllines with established cell signaling profiles in order to generatefurther understanding of GAP-107B8's efficacy in slowing proliferation,its time course of effect in cells, dose level response patterns, andinhibition of known cell signaling targets.
In the dose levels of 10, 15, and 20 micromolars (um),GAP107B8 slowed cell growth by, 29%, 62%, and 80% (average across allcell lines), showing a clear effect in slowing cancer cell proliferationand a clear effect of different dose levels.
Image analysis of cells over time showed biological effectsin cells in as early as 15 minutes, and inhibitory effect on signalingpathways was observed to be time-dependent and observed as early as 2hours following treatment. Inhibition of known cancer-related signalingpathways was observed in mTOR, MAPK, and PKC pathways (alpha and delta).
This in vitro test program will continue over thenext few weeks with additional analysis of GAP-107B8's mechanism onautophagic cell death, cell cycle effects in order to elucidateadditional mechanism of action information, and testing of the drugagainst normal, non-cancer cells in order to continue to establish thesafety profile of the drug.
"A series of tests are underway to provide the basis for selection of the cancer target for clinical trial application. I expect results from the pharmacokinetics program at the National ResearchCouncil, carried out in conjunction with Tandem Labs, to be availablenext week. I will be outlining the company's program to licensing at the Annual General Meeting later today, and we will report further on thatprogram in the next few days", Mr. McInnis said.
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is abiotechnology company with a core focus on developing novel peptidetherapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is anovel peptide drug that has been shown to be highly cytotoxic tonumerous cancer types, including chemo-resistant cancers, in vitro.For more information on PharmaGap please visit the Company's website atwww.pharmagap.com.
Note: Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracy ofthis release. No Securities Commission or other regulatory authorityhaving jurisdiction over PharmaGap has approved or disapproved of theinformation contained herein. This release contains forward lookingstatements that may not occur or may change materially.
For more information, please contact
PharmaGap Inc.
Robert McInnis
President & CEO
613-990-955
bmcinnis@pharmagap.com
or
PharmaGap Inc.
Martin Tremblay
IR Consultant
514-351-3736
IR@pharmagap.com
Clickhere to see all recent news from this company
TGen partner, PBS-Bio, makes first breakthrough drug analysis
Enables PharmaGap to advance development of promising anti-cancer drug
PHOENIX, Ariz. — June 18, 2010 — Predictive Biomarker Sciences Inc. (PBS-Bio) has completed its first drug analysis, enabling Canadian biotech company PharmaGap Inc. to significantly advance a potentially significant anti-cancer medication.
PharmaGap is an early-stage biotech company based in Ottawa, Ontario developing novel peptide compounds for cancer. Its lead compound, GAP-107B8, exhibits potent cytotoxic characteristics against cancer cells and has recently completed screening at the National Cancer Institute in Bethesda, Md., and was the subject of a data poster by researchers at the Ottawa Hospital Research Institute at the recent American Association for Cancer Research meeting in Washington, D.C. Proprietary real-time computer imaging technology from PBS-Bio has been instrumental in assisting PharmaGap to determine the drug's potential mechanism of action and thereby identifying suitable cancers to target for eventual clinical use.
As part of its pre-clinical development program, PharmaGap hired Phoenix-based PBS-Bio to analyze more specifically how the drug worked. PBS-Bio is a privately held, for-profit corporation owned in part by the non-profit Translational Genomics Research Institute (TGen). Data from the PBS-Bio analysis indicated that GAP-107B8 rapidly compromises the outer membrane of colorectal cancer cells, leading to either oncolytic or apoptotic cell death, while having significantly less affect on non-cancerous cells. Unlike many protein kinase inhibitor drugs now in development, GAP-107B8 works within mere minutes through "an assault on the plasma membrane," said Dr. Isabella Steffensen, a PharmaGap pre-clinical development consultant. She said that GAP-107B8 appears to be reacting with surface receptors apparently more prevalent on cancer cells than normal cells.
By providing PharmaGap with a more accurate analysis of how the drug functioned, PBS-Bio saved the company months of research and an estimated $400,000 in costs. Moreover, the PBS-Bio data has assisted PharmaGap to expand the scope of possible cancer targets for GAP-107B8, said Robert McInnis, the company's President and Chief Executive Officer. McInnis said PharmaGap is now also better positioned with GAP-107B8 to run clinical trials, anticipated in 2012, and expand the scope of its intellectual property and business development potential. "Based on the insights gleaned from working with the PBS-Bio team in Arizona, we have a much clearer idea of how this compound is acting," McInnis said. "Overall, it was a very successful collaboration. We certainly look forward to a continuing relationship with PBS-Bio"
Like plugging a computer diagnostic into a running car engine, PBS-Bio's technology uses live cancer cells to show pharmaceutical companies how their drugs work, or don't work, said Dr. Michael Bittner, Co-Director of TGen's Computational Biology Division. "For the first time, we can show — at the molecular level — exactly how drugs will affect cancer cells in real-time, identifying precisely along which cellular pathways drugs produce results, or fail,'' said Dr. Bittner, who also is a Principal Investigator at TGen for the PBS-Bio technology, and a Member of PBS-Bio's Scientific Advisory Board. "The success of targeted oncology drugs can vary from tumour to tumour, and the range of the specific types of tumour molecular pathologies that are susceptible or resistant to a given drug are frequently unknown. The purpose of the PBS-Bio technology is to make pre-clinical research more predictive of actual patient outcomes," Dr. Bittner said.
The technology is expected to save pharmaceutical companies millions of dollars in drug development costs, especially by showing what drugs might not work, thereby avoiding costly clinical trials, said Dr. Edward Smith, founder and CEO of PBS-Bio. The technology also is expected to show which drugs might work better in tandem with other drugs, thereby salvaging promising drug lines that otherwise might be shelved, said Dr. Smith, who also is an adjunct faculty member at TGen and at the University of Arizona College of Medicine. "Specifically, the TGen-PBS-Bio technology shows, in real time, how drugs affect the genes and their signalling pathways within cells that cause cancers to grow out of control," Dr. Smith said.
The hope is that by using this technology, drug companies will be able to develop cancer drugs more quickly, and at lower costs, while giving researchers a better idea of which patients will best respond to the therapies, Dr. Smith said.
PBS-Bio is working with three large pharmaceutical companies on projects to: determine which of several similar compounds to move into clinical trials, identify which drugs to add to their investigational drug to make it most effective, and identify biomarker tests that will identify patients most likely to respond to the new drug combination.
###
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF), based in Ottawa, Ontario, is a biotechnology company with a core focus on developing novel peptide therapeutics for the treatment of cancer. For more information please visit www.pharmagap.com.
Press contact:
Robert McInnis
PharmaGap President & CEO
613-990-9551
bmcinnis@pharmagap.com
About PBS-Bio
Predictive Biomarker Sciences Inc. (PBS-Bio) is a privately held corporation based in Mesa, Arizona, and founded in 2006 with funding from private investors, mostly based in Arizona. In addition to Dr. Bittner, a biologist, and Dr. Smith, a medical doctor, the TGen/PBS-Bio collaborative team includes Dr. Edward Dougherty, an electrical engineer and the other Co-Director of TGen's Computational Biology Division. The three began their collaborations while working under TGen President and Research Director Dr. Jeffrey Trent when Dr. Trent was the Scientific Director of the National Human Genomics Research Institute in Bethesda, Md. Their professional relationships continued after TGen was founded in Phoenix in 2002. For more information, please visit: pbs-bio.com.
Press contact:
Dr. Ed Smith, M.D.
President and CEO
602-418-9300
edsmith@pbs-bio.com
About TGen
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, please visit: www.tgen.org.
Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
syozwiak@tgen.org
Looking good Karin
Good one. I need to figure out how to play more and work less.
Weird... Just the talk of golfing and GAP starts going up.
There shouldn't be any dry patches this time around.
Going to play Elk Island tomorrow I think.
That guy could make the most boring game sounds exciting.